Stock CRNO B CERENO SCIENTIFIC AB (PUBL)
Add to a list
To use this feature you must be a member
Log inSign up

All News Cereno Scientific AB (publ) NORDIC GROWTH MARKET

Equities

CRNO B

SE0008241558

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 18:00:00 2023-06-19 EDT 		5-day change 1st Jan Change
0.521 SEK -7.13% Intraday chart for Cereno Scientific AB (publ) +7.98% -76.90%
04-16 Cereno Scientific AB Approves Election of New Directors CI
04-11 Cereno Scientific Secures Patent Expansion in Canada for Hypertension Drug Candidate MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Report from Annual General Meeting 2024 of Cereno Scientific AB
AQ
Cereno Scientific AB Approves Election of New Directors
CI
Cereno Scientific Secures Patent Expansion in Canada for Hypertension Drug Candidate
MT
Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family
AQ
Cereno Scientific Files Clinical Trial Application for Blood Cut Treatment
MT
Cereno Scientific submits Clinical Trial Application (CTA) for first-in-human Phase I study with novel epigenetic HDACi drug candidate CS014
AQ
Cereno Scientific AB Submits Clinical Trial Application for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014
CI
Cereno Scientific Receives Patent Expansion in Europe
MT
Cereno Scientific announces extended patent protection in Europe for CS585 program
AQ
Cereno Scientific releases Insights Video Season 3 Episode 9 with Dr. Björn Dahlöf, CSO, Cereno Scientific
AQ
Cereno Scientific participates at the ISHLT 44th Annual meeting and Scientific sessions to expand network and meet with investigators for the Phase II Study in PAH
AQ
Cereno Scientific releases Insights Video Season 3 Episode 8 with Björn Dahlöf, CSO, Cereno Scientific
AQ
Cereno Scientific publishes Annual Report for 2023
AQ
Cereno Scientific participates at the upcoming medical conference ACC.24 to further build presence in the Cardiology community
AQ
Cereno Scientific Obtains New European Patent for Hypertension Drug Candidate
MT
Cereno Scientific announces new patent issued in 25 European countries for Phase II drug candidate CS1
AQ
Cereno Scientific announces that a study protocol synopsis for the FDA approved Expanded Access Program for CS1 in PAH has been published on ClinicalTrials.gov
AQ
Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH
CI
Warrants of series TO3 were exercised to approximately 99.6 percent and Cereno Scientific receives approximately SEK 76.7 million
AQ
Cereno Scientific announces new patent issued in Mexico for Phase II drug candidate CS1
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRNO B Stock
  4. CRNO B Stock
  5. News Cereno Scientific AB (publ)